Nektar Therapeutics (NKTR) Misses Q1 EPS by 1c, Miss on Revenues
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $71.04 --0%
Revenue Growth %: -7.1%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
CRMT, PKE, More
Revenue Growth %: -7.1%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.42), $0.01 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $26.8 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- UBS Upgrades Charoen Pokphand Foods (CPF:TB) to Buy
- TD Cowen Upgrades Flagstar Bank (FLG) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
